2型糖尿病患者踝肱指数与血清抵抗素的相关性研究

目的：探讨初诊2型糖尿病患者踝肱指数（ABI）与血清抵抗素水平的相关性。方法：选取113例新诊断的2型糖尿病患者（T2DM）,其中根据ABI分为两组：ABI≥0.9组（n=71）和ABI〈0.9组（n=42）。采用酶联免疫吸附（ELISA）法检测血清抵抗素水平,并由专人采用ES-1000SPM多普勒血流探测仪检测ABI。结果：①ABI〈0.9组患者的年龄、糖尿病病程、收缩压（SBP）、空腹血糖、尿清蛋白及视网膜病变发生率等明显高于ABI≥0.9组患者（P〈0.05）;ABI〈0.9组患者血清抵抗素水平明显高于ABI≥0.9组患者（P〈0.01）,而且,经校正性别、年龄、BMI和病程后,两组间的差异具有统计学意义（P=0.045）。②Spearman相关性分析结果显示,ABI与年龄、病程、SBP、LDL-C、HbA1c、尿清蛋白和血清抵抗素具有显著相关性（P〈0.05）;而且,经校正性别、年龄、BMI和病程后,ABI仍与血清抵抗素水平显著相关（r=0.201,P=0.041）。结论：T2DM患者ABI与血清抵抗素显著相关,抵抗素可能是糖尿病心血管病变的重要危险因素之一。

Relationship between serum resistin concentration and ankle-brachial index in patients with type 2 diabetes

Objective： To investigate the relationship between serum resistin concentration and ankle-brachial index （ABI） in patients with type 2 diabetes. Methods： Fasting serum resistin concentration was measured with enzyme-linked immunosorbent assay （ELISA） in 113 patients with type 2 diabetes. These patients were divided into two groups： ABI≥0.9 group （n=71） and ABI〈0.9 group （n=42）. Results： The age, duration of diabetes, systolic blood pressure （SBP）, fasting blood glucose, urine albumin and the incidence of retinopathy in ABI〈0.9 group was significantly higher than that in ABI ≥0.9 group （P〈0.05）; The fasting serum resistin concentration in ABI〈0.9 group was significantly higher than that in ABI≥ 0.9 group （P〈0.01）. After adjusting for age, sex, body mass index （BMI） and known-duration of diabetes, the serum resistin level in ABI〈0.9 group was still significantly higher than that in ABI≥0.9 group （P=0.045）. Spearman analyzed shows that ABI was significantly correlated with age, known-duration of diabetes, SBP, LDL-C, HbAc, urinary albumin excretion and serum resistin level （P〈0.05）. After adjusting for age, sex, BMI and known-duration of diabetes, ABI was still significantly correlated with serum resistin level （r=0.201, P=0.041）. Conclusion： This study indicated that ABI is related to serum resistin concentration in patients with type 2 diabetes, resistin may be one of the important risk factors for cardiovascular disease.